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Mal de Meleda (MDM) is a rare, autosomal recessive form of palmoplantar keratoderma. It is characterized by erythema and
hyperkeratosis of the palms and soles that progressively extend to the dorsal surface of the hands and feet. It is caused by mutations
in SLURP-1 gene encoding for secreted mammalian Ly-6/uPAR-related protein 1 (SLURP-1). We performed mutational analysis by
direct sequencing of SLURP-1 gene in order to identify the genetic defect in three unrelated families (families MDM-12, MDM-13,
and MDM-14) variably affected with transgressive palmoplantar keratoderma. A spectrum of clinical presentations with variable
features has been observed from the pronounced to the transparent hyperkeratosis. We identified the 82delT frame shift mutation
in the SLURP-1 gene in both families MDM-12 and MDM-13 and the missense variation p.Cys99Tyr in family MDM-14. To date,
the 82delT variation is the most frequent cause of MDM in the world which is in favour of a recurrent molecular defect. The
p.Cys99Tyr variation is only described in Tunisian families making evidence of founder effect mutation of likely Tunisian origin.
Our patients presented with very severe to relatively mild phenotypes, including multiple keratolytic pits observed for one patient
in the hyperkeratotic area which was not previously reported. The phenotypic variability may reflect the influence of additional
factors on disease characteristics. This report further expands the spectrum of clinical phenotypes associated with mutations in
SLURP1 in the Mediterranean population.
1. Introduction
In North African populations, genetic transmission indicates
a relative abundance of recessive disorders that is clearly
associated with consanguineous unions [1]. Mal de Meleda
(MDM; OMIM 248300) is a rare autosomal recessive skin
disease with a prevalence in the general population estimated
to be 1 in 100 000. Meleda refers to an Adriatic island of
the Dalmatia region of Croatia, where the occurrence of the
disease as an entity of its own among the various forms of
Keratosis palmoplantaris hereditaria was first described [2].
The largest MDM series were reported from North Africa:
Tunisia (11 families with 45 patients) and Algeria (16 families
with 21 patients) [3, 4]. MDM is characterized by erythema
and hyperkeratosis of the palms and soles, extending to the
dorsal aspects of the hands and feet (known as transgrediens)
and perioral erythema and psoriasiform plaques on the
elbows and knees. At the histological level, hyperkeratosis,
hypergranulosis, and acanthosis are observed [5]. There are
no specific therapies to correct the underlying genetic defect
due to mutations in SLURP-1 gene located on chromosome
8q24.3. Until now, the most significant molecular advance of
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this disease has been the identification of causative mutations
and the analysis of the biological role of SLURP-1 protein in
the epidermis [6].
The results of previous laboratory studies showed the
distribution of only four MDM mutations in North Africa
p.Cys99Tyr (5 families), p.Cys77Ala (2 families), p.Gly86Arg
(1 family), and 82delT (17 families).Themutations previously
reported in Tunisian families were p.Cys99Tyr, p.Cys77Ala,
and 82delT.
Herein, we further describe three new Tunisian MDM
families with the mutations 82delT and p.Cys99Tyr and
presenting higher phenotypic variability.
2. Materials and Methods
2.1. Subjects. Three unrelated pedigrees of Tunisian descent
with MDM phenotype (families MDM-12, MDM-13, and
MDM-14) were referred to our laboratory to confirm diag-
nosis of MDM phenotype. In families MDM-12 and MDM-
13, there was only one affected individual (aged of 40 years).
In family MDM-14, there was 2 affected siblings that aged 2
and 13 years, respectively. The family history disclosed that
the parents in families MDM-12 and MDM-14 are double
and first cousins, respectively, whereas in family MDM-13,
no consanguineous relationship between the parents was
known. In all families, the parents were endogamous without
any skin symptoms andMDMwas inherited in an autosomal
recessive manner (Table 1). Ethical guidelines were followed,
and informed consent was obtained from all participants for
the genetic investigation.
2.2. Mutational Analysis. Blood samples were drawn from
each participant family member. DNA extraction from
peripheral blood leucocytes was performed using standard
procedures. Mutation analysis was carried out in the affected
members. All exons of the SLURP-1 gene with adjacent
sequences of exon-intron borders were amplified by PCR
with primers and conditions described previously [4]. Muta-
tion screening was performed by direct sequencing using Big
Dye terminator technology (ABI 3130), and sequences were
analyzed using Bioedit packages.
2.3. Generation of SLURP-1 Molecular Models. A model of
the three-dimensional structure of SLURP-1 protein wild
type and with p.Cys99Tyr variation was realized in order to
assess the potential effect of p.Cys99Tyr mutation on the 3D
conformation of SLURP-1 protein. In silico, modeling was
performed by using I-Tasser online server [7] and PyMOL
viewer [8].
3. Results and Discussion
3.1. Results
3.1.1. Clinical Findings. In family MDM-12, the patient is the
offspring of parents with double consanguinity. She exhib-
ited abnormal keratinization and yellowish erythematous
lesions. The age of onset was during the first months of
life. Yellow keratoderma of the palms and soles was outlined
by a red scaly border in a “glove-and-socks” distribution.
Hyperkeratosis spreads from the palms and soles to other
parts of the body, such as dorsal aspects of the hands and
feet, elbows, knees, perioral regions, and lower legs. Conical
distal phalanges and nail changes including thickening of
the nails were also noted. This phenotype resulted in severe
functional restriction of the hands and feet (Figures 1(a) and
1(b)). In this family, two nonaffected members presented
visual impairment problems. The patient in family MDM-13
presented the main clinical features of MDM without other
types of complications. In both families,MDM-12 andMDM-
13, there was no improvement of the hyperkeratosis with age.
In family MDM-14, the two affected siblings were still
young (2 and 13 years). They presented with a mild MDM
phenotype characterized by slightly erythematous keratotic
plaques that were light red in color and not perfectly appar-
ent. Multiple small keratolytic pits were observed over the
palmoplantar surface (Figures 1(c) and 1(d)). They consist
of 2–5mm pits outlined by brownish red erythema. They
were variably distributed on the hyperkeratosis area andmore
frequently on the plantar surface. The rest of the skin was
normal.
Table 2 summarizes the clinical characteristics of all the
studied patients.
3.1.2. Mutational Analysis. In families MDM-12 and MDM-
13, sequencing of PCR-amplified SLURP1 gene revealed the
existence of a nucleotide deletion, 82delT at homozygous
state in the affected individuals. This frame shift variation is
leading to a creation of a premature stop codon at amino acid
position 32 within exon 2 and to the synthesis of a truncated
protein.
In family MDM-14, we identified a missense mutation
which changes G to A at nucleotide position 297 within exon
3. It leads to an amino acid change from cysteine to tyrosine
at codon 99 (p.Cys99Tyr) (Table 1).
3.1.3. Comparative Modeling of SLURP-1 Three-Dimensional
Structures. Comparative modeling of SLURP-1 wild type and
SLURP-1 with p.Cys99Tyr variation showed difference in the
protein 3D conformation. The p.Cys99Tyr probably desta-
bilizes the whole structure and particularly the third loop
of the three-finger fold by changing the folding properties
(Figure 2).
3.2. Discussion. The high consanguinity rates, coupled to the
large family size in some communities, could induce the
expression of autosomal recessive diseases, including new or
very rare disorders such as MDM. Limited number of MDM
cases was reported in several parts of the world [3, 4, 9–
11]. The major reported cases of MDM in North Africa are
of Tunisian descent with a total of 49 patients including
the patients reported herein [3, 4, 12]. MDM is caused by
mutations in SLURP-1 gene encoding for SLURP-1 protein.
SLURP-1 consisted of 103 amino acids and five disulfide
bridges that are critical for the correct folding and function of
the protein. SLURP1 potentiates the action of acetylcholine on
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(a) (b)
(c) (d)
Figure 1: Clinical manifestations of MDM. Pronounced yellowish erythematous transgrediens palmoplantar keratoderma over the hands
and feet of patient belonging to family MDM-12 ((a)-(b)). Transparent hyperkeratosis with red border delimiting the hyperkeratotic area and







Figure 2: In silico modeling of the SLURP1 wild type (a) and SLURP1 with the p.Cys99Tyr mutation (b). The model shows the possible
structural differences between the mutant and wild-type proteins. The presence of the p.Cys99Tyr variation led to a new protein folding
missing the loops conformation. Structures are determined from amino acid sequences with I-Tasser online server and figures produced with
PyMOL viewer. The p.Cys99Tyr variation position is showed by red.
the 𝛼7 nicotinic receptor [13], which plays an important role
in the differentiation of stratified squamous epithelium [6,
14]. To date, only fourteen SLURP-1mutations were described
in relation withMDMphenotype.Three of them are reported
in Tunisia: C77A, 82delT, and p.Cys99Tyr (Figure 3).
In this report, we further characterize new MDM cases
from Tunisia. Three families were recruited with variable
clinical features of MDM. We found the 82delT variation
commonly in families MDM-12 and MDM-13. This frame
shift mutation results in truncated, misfolded, and therefore
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Table 2: Clinical characteristics of the Mal de Meleda patients.
Patient’s characteristics Patient in family MDM-12 Patient in family MDM-13 Patients in family MDM-14
Patient 1 Patient 2
Age (years) 40 40 2 13
Age of onset First months First months First months First months
Sex F M M F
Diffuse hyperkeratosis ++ ++ + +
Characteristics of transgressiveness + + + ++ + +
Elbows involvement ++ − − −
Knees involvement ++ − − −
Palmoplantar hyperhidrosis ++ + − −
Malodor pachyderma + + + ++ + +
Nails involvement + + + ++ ++ ++
Perioral erythema + + + + − −
Keratolytic pits − − ++ ++





















Ivs1 + 1G > A
Ivs2 + 1G > A
Arg71His (patient origin not determined)
Figure 3: Geographic distribution of the SLURP-1 gene reported
mutations.Met1Lys (Emirates Bedouin [15]); Ivs1 + 1G>A(Pakistani
[16]); Trp15Arg (German [15], Scottish [3], and Dutch [17]); 82delT
(Tunisian [3], Scottish [3], Algerian [3], Croatian [9], Kurdish [10],
and Italian [11]); Ivs2 + 1G > A (Algerian [3]); Cys43Stop (Turkish
[18]); Arg71Pro (Dutch [17]); Cys77Ala (Tunisian [4]); Pro82Ser
(Turkish [19]); Gly86Arg (Palestinian [15], Turkish [15]), and Pak-
istani [16]), Korean [20], Taiwanese [21]); Arg96Stop (Croatian [9],
Turkish [10], Korean [20], and Pakistani [16]); Lys98Pro (Turkish
[22]); Cys99Tyr (Tunisian [12]); and Arg71His (patient was reported
in a study from France, and the origin is not reported [23]).
nonfunctional protein. The 82delT variation was previously
identified across several ethnicities (Tunisian, Scottish, Alge-
rian, Croatian, Kurdish, and Italian). It seems to be specific
to the Mediterranean region (including 7 Tunisian and 10
Algerian families) suggesting the existence of a founder
effect likely of Mediterranean origin where intermarriage is
common [24].
The p.Cys99Tyr variation was identified in family MDM-
14 that originated from the South of Tunisia. It affects a
cysteine implicated in one of the highly conserved disulfide
bridges. Although p.Cys99Tyr is towards the end of the
protein, 3D folding showed that thismutationwhich is within
loop3 of SLURP-1 caused difference in the 3D structure
compared to the wild-type SLURP-1. It was suggested that
mutations involving amino acids in loop3 might affect the
binding of SLURP-1 to 𝛼7-nAchR [23]. The p.Cys99Tyr
variation was previously identified only in Tunisian families
[3, 4]. This sharp geographical demarcation is suggestive of
a founder effect of Tunisian origin. Nevertheless, since some
populations like Libya,Morocco, and Egypt have not yet been
investigated, a more extended geographical distribution of
this mutation could not be ruled out.
Comparing the disease severity between the studied
families, we observed that the clinical picture varied from
severe to milder transparent hyperkeratosis. The most severe
phenotype was observed in family MDM-12; however, the
two other patients presented a moderate phenotype. In
family MDM-14, multiple keratolytic pits were observed in
the hyperkeratotic area which was not previously reported.
Although these unusual keratolytic pits appeared in early
infancy in the palmoplantar area, the phenotype in both
affected patients is currently moderate but might exacerbate
with age and exposure to mechanical or heat trauma.
In the literature, The extensive scarring on the hands and
feet could be associated with melanoma development. Three
cases of malignant melanoma arising in the hyperkeratotic
lesions of MDM have been described in the literature at
late age [21, 25, 26]. One case with classical clinical MDM
finding complicated by irregular hyperpigmented spots on
the palmoplantar regions and the back of hands and feet was
also reported [27]. We think that unfavorable environmental
factors and either bacterial or fungal infection play a major
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role in the worsening of MDM and may increase the skin
thickening. No melanoma symptoms were observed so far
in our cases even in family MDM-12 presenting the most
pronounced MDM phenotype, but it could occur at late age.
4. Conclusion
In this report, we further characterize new MDM cases
and identified the responsible mutations. In Tunisia, the
MDM patients become aware of the risk to transmit the
condition to the offspring.Therefore, we believe that it is very
important to inform affected families about heterozygous
carriers to avoid other consanguineous marriages. While
the mutational findings have improved the understanding of
MDMphenotype, it is necessary to continue with therapeutic
assays of SLURP-1. The function of this protein needs to
be further elucidated, and therapeutic approaches for this
palmoplantar keratoderma are highly required.
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